Pharmacological, toxicological, and dose range assessment of OG716, a novel lantibiotic for the treatment of clostridium difficile-associated infection

Mark E. Pulse, William J. Weiss, Johan A. Kers, Anthony W. DeFusco, Jae H. Park, Martin Handfield

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lantibiotics present an attractive scaffold for the development of novel antibiotics. We report here a novel lantibiotic for the treatment of Clostridium difficile infection. The lead compounds were selected from a library of over 700 single- and multiple-substitution variants of the lantibiotic mutacin 1140 (MU1140). The best performers in vitro and in vivo were further used to challenge Golden Syrian hamsters orally in a Golden Syrian hamster model of Clostridium difficile-associated disease (CDAD) in a dose-response format, resulting in the selection of OG716 as the lead compound. This lantibiotic was characterized by a 50% effective dose of 23.85 mg/kg of body weight/day (10.97 mol/kg/day) in this model. Upon oral administration of the maximum feasible dose (1,918 mg/kg/day), no observable toxicities or side effects were noted, and no effect on intestinal motility was observed. Compartmentalization to the gastrointestinal tract was confirmed. MU1140-derived variants offer a large pipeline for the development of novel antibiotics for the treatment of several indications and are particularly attractive considering their novel mechanism of action. Based on the currently available data, OG716 has an acceptable profile for further development for the treatment of CDAD.

Original languageEnglish
Article numbere01904-18
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number4
DOIs
StatePublished - Apr 2019

Fingerprint

Bacteriocins
Clostridium difficile
Toxicology
Pharmacology
Mesocricetus
Infection
Anti-Bacterial Agents
Clostridium Infections
Gastrointestinal Motility
Therapeutics
Libraries
Oral Administration
Gastrointestinal Tract
Body Weight
Lead
mutacin 1140

Keywords

  • Antibiotic
  • Antibiotic resistance
  • Antimicrobial peptide
  • Bacteriocin
  • Bioavailability
  • Lanthipeptide
  • Lantibiotic
  • Mutacin
  • Mutagenesis
  • Nisin

Cite this

@article{82909d8b573c4fa285cbfb504c2cf9d9,
title = "Pharmacological, toxicological, and dose range assessment of OG716, a novel lantibiotic for the treatment of clostridium difficile-associated infection",
abstract = "Lantibiotics present an attractive scaffold for the development of novel antibiotics. We report here a novel lantibiotic for the treatment of Clostridium difficile infection. The lead compounds were selected from a library of over 700 single- and multiple-substitution variants of the lantibiotic mutacin 1140 (MU1140). The best performers in vitro and in vivo were further used to challenge Golden Syrian hamsters orally in a Golden Syrian hamster model of Clostridium difficile-associated disease (CDAD) in a dose-response format, resulting in the selection of OG716 as the lead compound. This lantibiotic was characterized by a 50{\%} effective dose of 23.85 mg/kg of body weight/day (10.97 mol/kg/day) in this model. Upon oral administration of the maximum feasible dose (1,918 mg/kg/day), no observable toxicities or side effects were noted, and no effect on intestinal motility was observed. Compartmentalization to the gastrointestinal tract was confirmed. MU1140-derived variants offer a large pipeline for the development of novel antibiotics for the treatment of several indications and are particularly attractive considering their novel mechanism of action. Based on the currently available data, OG716 has an acceptable profile for further development for the treatment of CDAD.",
keywords = "Antibiotic, Antibiotic resistance, Antimicrobial peptide, Bacteriocin, Bioavailability, Lanthipeptide, Lantibiotic, Mutacin, Mutagenesis, Nisin",
author = "Pulse, {Mark E.} and Weiss, {William J.} and Kers, {Johan A.} and DeFusco, {Anthony W.} and Park, {Jae H.} and Martin Handfield",
year = "2019",
month = "4",
doi = "10.1128/AAC.01904-18",
language = "English",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

Pharmacological, toxicological, and dose range assessment of OG716, a novel lantibiotic for the treatment of clostridium difficile-associated infection. / Pulse, Mark E.; Weiss, William J.; Kers, Johan A.; DeFusco, Anthony W.; Park, Jae H.; Handfield, Martin.

In: Antimicrobial agents and chemotherapy, Vol. 63, No. 4, e01904-18, 04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacological, toxicological, and dose range assessment of OG716, a novel lantibiotic for the treatment of clostridium difficile-associated infection

AU - Pulse, Mark E.

AU - Weiss, William J.

AU - Kers, Johan A.

AU - DeFusco, Anthony W.

AU - Park, Jae H.

AU - Handfield, Martin

PY - 2019/4

Y1 - 2019/4

N2 - Lantibiotics present an attractive scaffold for the development of novel antibiotics. We report here a novel lantibiotic for the treatment of Clostridium difficile infection. The lead compounds were selected from a library of over 700 single- and multiple-substitution variants of the lantibiotic mutacin 1140 (MU1140). The best performers in vitro and in vivo were further used to challenge Golden Syrian hamsters orally in a Golden Syrian hamster model of Clostridium difficile-associated disease (CDAD) in a dose-response format, resulting in the selection of OG716 as the lead compound. This lantibiotic was characterized by a 50% effective dose of 23.85 mg/kg of body weight/day (10.97 mol/kg/day) in this model. Upon oral administration of the maximum feasible dose (1,918 mg/kg/day), no observable toxicities or side effects were noted, and no effect on intestinal motility was observed. Compartmentalization to the gastrointestinal tract was confirmed. MU1140-derived variants offer a large pipeline for the development of novel antibiotics for the treatment of several indications and are particularly attractive considering their novel mechanism of action. Based on the currently available data, OG716 has an acceptable profile for further development for the treatment of CDAD.

AB - Lantibiotics present an attractive scaffold for the development of novel antibiotics. We report here a novel lantibiotic for the treatment of Clostridium difficile infection. The lead compounds were selected from a library of over 700 single- and multiple-substitution variants of the lantibiotic mutacin 1140 (MU1140). The best performers in vitro and in vivo were further used to challenge Golden Syrian hamsters orally in a Golden Syrian hamster model of Clostridium difficile-associated disease (CDAD) in a dose-response format, resulting in the selection of OG716 as the lead compound. This lantibiotic was characterized by a 50% effective dose of 23.85 mg/kg of body weight/day (10.97 mol/kg/day) in this model. Upon oral administration of the maximum feasible dose (1,918 mg/kg/day), no observable toxicities or side effects were noted, and no effect on intestinal motility was observed. Compartmentalization to the gastrointestinal tract was confirmed. MU1140-derived variants offer a large pipeline for the development of novel antibiotics for the treatment of several indications and are particularly attractive considering their novel mechanism of action. Based on the currently available data, OG716 has an acceptable profile for further development for the treatment of CDAD.

KW - Antibiotic

KW - Antibiotic resistance

KW - Antimicrobial peptide

KW - Bacteriocin

KW - Bioavailability

KW - Lanthipeptide

KW - Lantibiotic

KW - Mutacin

KW - Mutagenesis

KW - Nisin

UR - http://www.scopus.com/inward/record.url?scp=85063667753&partnerID=8YFLogxK

U2 - 10.1128/AAC.01904-18

DO - 10.1128/AAC.01904-18

M3 - Article

C2 - 30670434

AN - SCOPUS:85063667753

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

M1 - e01904-18

ER -